Desmopressin acetate in cardiac surgery: a double-blind, randomized study

Area of Science:

• Cardiovascular Surgery
• Anesthesiology
• Hematology

Background:

• The efficacy of desmopressin acetate (DDAVP) in reducing perioperative bleeding during cardiac surgery remains a subject of debate.
• Previous studies have yielded conflicting results regarding DDAVP's effectiveness in this patient population.

Purpose of the Study:

• To evaluate the impact of desmopressin acetate (DDAVP) on bleeding in patients undergoing cardiac surgery.
• To compare blood loss, transfusion requirements, and laboratory parameters between DDAVP and placebo groups.

Main Methods:

• A double-blind, randomized study was conducted with 83 patients undergoing cardiac operations.
• Patients were allocated to receive either DDAVP or a placebo.
• Bleeding was assessed by measuring total blood loss over 24 hours postoperatively, replacement fluid volume, and relevant laboratory tests.

Main Results:

• No significant differences were observed in baseline or intraoperative characteristics between the DDAVP and placebo groups.
• Mean 24-hour postoperative drainage was 1,214 mL for the DDAVP group and 1,386 mL for the placebo group (p > 0.05).
• There were no statistically significant differences in the need for blood product replacement between the two groups.

Conclusions:

• Administration of desmopressin acetate (DDAVP) did not demonstrate a significant reduction in bleeding for patients undergoing cardiac surgery in this study.
• The findings suggest that DDAVP may not be an effective intervention for managing bleeding in this specific surgical context.
• Further research may be warranted to explore potential patient subgroups or alternative strategies for bleeding management in cardiac surgery.